LENSAR (NASDAQ:LNSR) Releases Quarterly Earnings Results, Beats Estimates By $0.26 EPS

LENSAR (NASDAQ:LNSR) released its quarterly earnings results on Thursday. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.26, Zacks reports. LENSAR had a net margin of 50.94% and a negative return on equity of 183.19%.

Here are the key takeaways from LENSAR’s conference call:

• Q2 revenue increased 18% year over year to $16.5 million, while recurring revenue rose 20% to $13.7 million and procedure revenue grew 23% to $10.2 million.
• LENSAR placed 10 ALLY systems during the quarter, expanding the global installed base to approximately 445 systems, with 13 ALLY systems in backlog; procedure volume increased 13% to 58,682 and U.S. procedure market share reached 24.1%.
• The company reported its strongest adjusted EBITDA performance to date at $3.6 million, supported by revenue growth, a greater mix of recurring revenue, and lower expenses; gross margin was 52% excluding a $1.1 million tariff refund.
• Cash and equivalents declined to $13.6 million from $18 million at year-end 2025, and management expects operating expenses to rise toward historical levels as it increases commercial investment, creating potential variability in EBITDA over the next several quarters.
• Management cautioned that third-quarter cataract procedure volumes are historically lower because of seasonal holidays and vacations, while rebuilding overseas distributor relationships is expected to take several quarters.

LENSAR Stock Performance

Shares of NASDAQ LNSR traded up $1.75 during midday trading on Thursday, reaching $8.04. The stock had a trading volume of 1,822,055 shares, compared to its average volume of 93,640. The firm has a market cap of $98.79 million, a price-to-earnings ratio of -13.74 and a beta of 0.89. LENSAR has a twelve month low of $4.95 and a twelve month high of $12.96. The company’s 50 day moving average price is $5.79 and its 200 day moving average price is $7.40.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Weiss Ratings restated a “sell (d+)” rating on shares of LENSAR in a report on Friday, August 7th. Wall Street Zen downgraded LENSAR from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, BTIG Research upped their price target on LENSAR from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $9.50.

Institutional Investors Weigh In On LENSAR

Several large investors have recently modified their holdings of LNSR. BNP Paribas Financial Markets grew its position in shares of LENSAR by 129.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,008 shares of the company’s stock worth $25,000 after buying an additional 1,131 shares during the period. JPMorgan Chase & Co. lifted its position in shares of LENSAR by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,928 shares of the company’s stock valued at $73,000 after acquiring an additional 1,254 shares during the period. Barclays PLC boosted its stake in LENSAR by 10.3% during the fourth quarter. Barclays PLC now owns 14,857 shares of the company’s stock worth $173,000 after acquiring an additional 1,389 shares in the last quarter. Vanguard Group Inc. boosted its stake in LENSAR by 0.3% during the third quarter. Vanguard Group Inc. now owns 507,603 shares of the company’s stock worth $6,269,000 after acquiring an additional 1,446 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in LENSAR by 11.8% in the third quarter. Envestnet Asset Management Inc. now owns 15,277 shares of the company’s stock worth $189,000 after purchasing an additional 1,611 shares during the period. 40.15% of the stock is currently owned by institutional investors and hedge funds.

LENSAR Company Profile

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.